Edition:
United States

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

25.75USD
24 Sep 2018
Change (% chg)

$0.50 (+1.98%)
Prev Close
$25.25
Open
$25.16
Day's High
$25.75
Day's Low
$25.16
Volume
618
Avg. Vol
2,835
52-wk High
$39.50
52-wk Low
$19.28

Latest Key Developments (Source: Significant Developments)

Beyondspring Qtrly Loss Per Share $0.68
Tuesday, 3 Apr 2018 07:00am EDT 

April 3 (Reuters) - BeyondSpring Inc ::PROVIDES OPERATIONAL UPDATE AND FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.68.CASH AND CASH EQUIVALENTS WERE $30.6 MILLION AT DEC. 31, 2017, COMPARED TO $40.7 MILLION AT SEPT. 30, 2017.BELIEVES HAS SUFFICIENT CASH RESOURCES TO ADVANCE ONGOING CLINICAL TRIALS IN LATE 2018 OR EARLY 2019 AND FIRST HALF OF 2019.  Full Article

BeyondSpring Says Richard Brand Resigned As CFO
Wednesday, 21 Feb 2018 08:23am EST 

Feb 21 (Reuters) - Beyondspring Inc ::BEYONDSPRING SAYS RICHARD A. BRAND RESIGNED AS CHIEF FINANCIAL OFFICER OF CO EFFECTIVE AS OF FEBRUARY 20, 2018 - SEC FILING.BEYONDSPRING INC - AMY YANG WILL CONTINUE TO SERVE AS CO'S CONTROLLER WHILE ACTING AS INTERIM CFO.  Full Article

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Beyondspring Inc ::BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN).BEYONDSPRING INC - INTERIM ANTI-CANCER EFFICACY DATA FROM PHASE 3 NSCLC CLINICAL TRIAL IS EXPECTED IN MID-2018.  Full Article

Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China
Thursday, 30 Nov 2017 09:58am EST 

Nov 30 (Reuters) - Beyondspring Inc ::BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY.BEYONDSPRING INC - ‍EXPECT CFDA FILINGS OF FIRST NDAS FOR BOTH CIN AND NSCLC INDICATIONS POTENTIALLY IN 2018​.  Full Article

BeyondSpring qtrly loss per share $‍0.68
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - BeyondSpring Inc :BeyondSpring reports third quarter 2017 operational and financial results.BeyondSpring Inc - qtrly loss per share $‍0.68​.  Full Article

BeyondSpring announces first patient enrolled in China
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - BeyondSpring Inc ::BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia.BeyondSpring-‍look forward to top line results, later in 2017, comparing plinabulin with pegfilgrastim from phase 2 portion of the phase 2/3 trial.  Full Article

China FDA approves ctas for Beyondspring's second global plinabulin registrational trial
Thursday, 6 Jul 2017 08:00am EDT 

July 6 (Reuters) - Beyondspring Inc ::China FDA approves ctas for beyondspring’s second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention.Beyondspring- approved company's clinical trial applications (ctas) to allow initiation of two global phase 2/3 trials for its lead asset, plinabulin.Beyondspring-Targeting reporting phase 2 efficacy data in 2h 2017, phase 3 interim data in 2018, submitting NDA in 2019 to FDA and CFDA for plinabulin.  Full Article

BeyondSpring prices initial public offering and concurrent private placement of $54.31 mln
Thursday, 9 Mar 2017 07:00am EST 

BeyondSpring Inc - : Prices initial public offering and concurrent private placement of $54.31 mln .Pricing of its initial public offering of 174,286 ordinary shares at a public offering price of $20.00 per share.  Full Article